Diabetes Mellitus, Type 1
Conditions
Keywords
Diabetes Mellitus, Type 1, Genetic Predisposition to Disease, Infant Nutrition, Primary Prevention
Brief summary
The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) is an international effort to conduct a primary prevention nutrition trial for type 1 (insulin-dependent) diabetes. The TRIGR study was targeted at newborns who are at genetic risk for type 1 diabetes because their mother, father and/or full sibling has type 1 diabetes. All families were encouraged to breast feed their infants for as long as possible. Prior to birth, the child was randomly assigned to receive one of two infant formulas, should formula be required prior to 8 months of age. The study determined whether weaning to a possibly protective infant formula decreases these children's chances of developing diabetes - as it does in the animal models for diabetes.
Detailed description
The hypothesis for this study is that weaning to an extensively hydrolyzed infant formula will decrease the incidence of type 1 diabetes in subjects with risk-associated HLA genotypes and a first degree relative with type 1 diabetes, as it does in all relevant animal models for the disease. Specific Aims: I.a: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of diabetes-predictive auto-antibodies in subjects with risk-associated HLA genotype and a first degree relative with type 1 diabetes (mother, father and/or full sibling). I-b: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of clinical diabetes in subjects with risk-associated HLA genotype and an affected first degree relative. A secondary aim is to determine relationships between cow's milk antibodies, a measure of cow's milk exposure, and diabetes-associated auto-antibodies. The mother of the unborn child is recruited during pregnancy. Randomization to one of two infant formulas takes place before birth (after 35 weeks gestation) or immediately after birth. Experimental Arm: Use of extensively hydrolysed cow's milk based infant formula when needed in supplementation or substitution for breast milk through 6-8 months from birth. Control Arm: Use of non-hydrolysed cow's milk based infant formula when needed in supplementation or substitution for breast milk through 6-8 months from birth. All families were encouraged to breast feed their infants for as long as possible. The study infant formula was only used if exclusive breast feeding ceases before 8 months of age. Cord blood for genotyping was obtained at birth, or failing that from a heel prick by 7 days of age. Only subjects with genotypes indicating increased genetic risk for type 1 diabetes remained in the intervention trial. All other subjects were withdrawn from the study. All subjects were followed until the youngest subject turns age 10 years.
Interventions
Participants in the Hydrolysed infant formula -group received the test formula, casein hydrolysate (Nutramigen™, Mead Johnson Nutritionals), not containing antigenic CM protein, whenever breast milk is not available.
Participants in the Nonydrolysed infant formula -group received the CM protein containing control formula which has an addition (20 %) of Nutramigen, whenever breast milk is not available.
Sponsors
Study design
Eligibility
Inclusion criteria
* Biological parent and/or full (not half) sibling of the newborn infant had type 1 diabetes as defined by the World Health Organization * The infant's parent or legal guardians gave signed consent to participate
Exclusion criteria
* An older sibling of the newborn infant had been included in the TRIGR intervention * Multiple gestation * The parents were unwilling or unable to feed the infant cow's milk based products for any reason (e.g., religious, cultural). * The newborn infant had a recognizable severe illness such as those due to chromosomal abnormality, congenital malformation, respiratory failure needing assisted ventilation, enzyme deficiencies, etc. * The gestational age of the newborn infant was less than 35 weeks. * The infant was older than 7 days at randomization. * Inability of the family to take part in the study (e.g. the family has no access to any of the Study Centers, the family has no telephone). * The infant had received any infant formula other than Nutramigen prior to randomization. * No HLA sample drawn before the age of 8 days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Type 1 Diabetes Mellitus | 12 and 18 months and annually from 2 years up to 14 years | Number of participants with Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age and in the final year of the study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Diabetes Associated Autoantibodies | 3, 6, 9, 12, 18 months and annually from 2 years up to 14 years | Diabetes associated autoantibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12, and 18 months of age, and annually from age 2 to 10-14 years |
Countries
Australia, Canada, Czechia, Estonia, Finland, Germany, Hungary, Italy, Luxembourg, Netherlands, Poland, Spain, Sweden, Switzerland, United States
Participant flow
Recruitment details
2002-2007 Recruited through local clinics and obstetrics unit
Participants by arm
| Arm | Count |
|---|---|
| Nonhydrolysed Infant Formula A conventional adapted cow's milk formula supplemented with 20% of the casein hydrolysate. | 1,078 |
| Hydrolysed Infant Formula Hydrolysed Infant Formula missing intact cows milk proteins | 1,081 |
| Total | 2,159 |
Baseline characteristics
| Characteristic | Nonhydrolysed Infant Formula | Hydrolysed Infant Formula | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 1078 Participants | 1081 Participants | 2159 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous Age at Last Follow-up | 11.96 years | 11.93 years | 11.95 years |
| Age, Continuous At at randomization | 0 years | 0 years | 0 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 53 Participants | 53 Participants | 106 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 987 Participants | 989 Participants | 1976 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 38 Participants | 39 Participants | 77 Participants |
| family history of type 1 diabetes More than one family member with type 1 diabetes | 32 Participants | 45 Participants | 77 Participants |
| family history of type 1 diabetes Only father with type 1 diabetes | 367 Participants | 355 Participants | 722 Participants |
| family history of type 1 diabetes Only mother with type 1 diabetes | 522 Participants | 530 Participants | 1052 Participants |
| family history of type 1 diabetes Only one sibling with type 1 diabetes | 157 Participants | 151 Participants | 308 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 3 Participants | 3 Participants | 6 Participants |
| Race (NIH/OMB) Asian | 10 Participants | 13 Participants | 23 Participants |
| Race (NIH/OMB) Black or African American | 10 Participants | 16 Participants | 26 Participants |
| Race (NIH/OMB) More than one race | 9 Participants | 6 Participants | 15 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 6 Participants | 9 Participants | 15 Participants |
| Race (NIH/OMB) White | 1040 Participants | 1034 Participants | 2074 Participants |
| Region of Enrollment Australia | 51 participants | 51 participants | 102 participants |
| Region of Enrollment Canada | 262 participants | 265 participants | 527 participants |
| Region of Enrollment Czechia | 82 participants | 82 participants | 164 participants |
| Region of Enrollment Estonia | 18 participants | 17 participants | 35 participants |
| Region of Enrollment Finland | 212 participants | 212 participants | 424 participants |
| Region of Enrollment Germany | 57 participants | 55 participants | 112 participants |
| Region of Enrollment Hungary | 12 participants | 11 participants | 23 participants |
| Region of Enrollment Italy | 26 participants | 28 participants | 54 participants |
| Region of Enrollment Luxembourg | 3 participants | 4 participants | 7 participants |
| Region of Enrollment Netherlands | 29 participants | 24 participants | 53 participants |
| Region of Enrollment Poland | 46 participants | 48 participants | 94 participants |
| Region of Enrollment Spain | 31 participants | 29 participants | 60 participants |
| Region of Enrollment Sweden | 47 participants | 49 participants | 96 participants |
| Region of Enrollment Switzerland | 6 participants | 37 participants | 43 participants |
| Region of Enrollment United States | 196 participants | 199 participants | 395 participants |
| Sex: Female, Male Female | 516 Participants | 505 Participants | 1021 Participants |
| Sex: Female, Male Male | 562 Participants | 576 Participants | 1138 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 5 / 1,078 | 5 / 1,081 |
| other Total, other adverse events | 1,010 / 1,078 | 1,012 / 1,081 |
| serious Total, serious adverse events | 379 / 1,078 | 377 / 1,081 |
Outcome results
Number of Participants With Type 1 Diabetes Mellitus
Number of participants with Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age and in the final year of the study.
Time frame: 12 and 18 months and annually from 2 years up to 14 years
Population: Analysis population consisted of participants with increased genetic risk (defined HLA genotypes) for type 1 diabetes
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Nonhydrolysed Infant Formula | Number of Participants With Type 1 Diabetes Mellitus | 82 participants |
| Hydrolysed Infant Formula | Number of Participants With Type 1 Diabetes Mellitus | 91 participants |
Number of Participants With Diabetes Associated Autoantibodies
Diabetes associated autoantibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12, and 18 months of age, and annually from age 2 to 10-14 years
Time frame: 3, 6, 9, 12, 18 months and annually from 2 years up to 14 years
Population: Analysis population consisted of participants with increased genetic risk (defined HLA genotypes) for type 1 diabetes
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Nonhydrolysed Infant Formula | Number of Participants With Diabetes Associated Autoantibodies | IAA+ | 162 Participants |
| Nonhydrolysed Infant Formula | Number of Participants With Diabetes Associated Autoantibodies | ICA+ | 373 Participants |
| Nonhydrolysed Infant Formula | Number of Participants With Diabetes Associated Autoantibodies | GADA+ | 186 Participants |
| Nonhydrolysed Infant Formula | Number of Participants With Diabetes Associated Autoantibodies | IA-2A+ | 102 Participants |
| Hydrolysed Infant Formula | Number of Participants With Diabetes Associated Autoantibodies | IA-2A+ | 115 Participants |
| Hydrolysed Infant Formula | Number of Participants With Diabetes Associated Autoantibodies | GADA+ | 207 Participants |
| Hydrolysed Infant Formula | Number of Participants With Diabetes Associated Autoantibodies | ICA+ | 394 Participants |
| Hydrolysed Infant Formula | Number of Participants With Diabetes Associated Autoantibodies | IAA+ | 183 Participants |